13.35
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com Australia
Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com India
Mineralys Therapeutics Executives Sell Shares - TradingView
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance
SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow
SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada
Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks
When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com
Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia
ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum
Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks
Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks
Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times
Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) - TradingView
Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan
Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - Marketscreener.com
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN
3 Brilliant Space Stocks to Buy Now and Hold for the Long Term - The Globe and Mail
Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire
Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times
Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan
MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus
Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues
Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - The Manila Times
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey
Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com
Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan
10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey
Mineralys to present hypertension drug trial results at ACC.25 By Investing.com - Investing.com Australia
大文字化:
|
ボリューム (24 時間):